Takeda clears US trade commission hurdle for $62b Shire acquisition

Shire logos sit on the boxes of Elvanse 50mg tablets, produced by Shire Plc, left, and Mezavant XL 1200mg tablets, produced by Shire Plc, in this arranged photograph taken at a pharmacy in London, U.K., on Tuesday, July 8, 2014. Photographer: Bloomberg/Bloomberg

Takeda Pharmaceutical Co. cleared a hurdle for its $62 billion acquisition of Shire Plc, receiving unconditional approval from the U.S. Federal Trade Commission two months after sealing its biggest deal ever.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Should your colleagues be reading this article too? Contact us for corporate subscriptions at subs@dealstreetasia.com.